Literature DB >> 6482312

Disposition of oxazepam in patients on maintenance hemodialysis.

H R Ochs, D J Greenblatt, U Klehr.   

Abstract

The pharmacokinetics of a single 30-mg oral dose of oxazepam was evaluated in seven patients with chronic renal failure on maintenance hemodialysis and in seven healthy controls matched for age and sex. Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02). However, total clearance was similar between groups (1.8 vs 1.9 ml/min per kilogram). These findings were confounded by the increased oxazepam free fraction in serum of renal failure patients (10.3%) as compared to healthy controls (4.3%). Correction for differences in binding indicates similar distribution of unbound oxazepam between groups, but reduced clearance of pharmacologically active unbound oxazepam in renal patients (18 vs 45 ml/min per kilogram). Oxazepam dosage, therefore, may require downward adjustment for renal failure patients on hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482312     DOI: 10.1007/bf01721774

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

Authors:  D J Greenblatt; K Franke; R I Shader
Journal:  J Chromatogr       Date:  1978-09-01

Review 2.  Drug therapy. Current status of benzodiazepines.

Authors:  D J Greenblatt; R I Shader; D R Abernethy
Journal:  N Engl J Med       Date:  1983-08-11       Impact factor: 91.245

3.  Oxazepam disposition in uremic patients.

Authors:  I Odar-Cederlöf; J Vessman; G Alván; F Sjöqvist
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-01

4.  Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.

Authors:  U Busch; M Molzahn; G Bozler; F W Koss
Journal:  Arzneimittelforschung       Date:  1981

5.  Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency.

Authors:  D J Greenblatt; T G Murray; P R Audet; A Locniskar; H H Koepke; B R Walker
Journal:  Nephron       Date:  1983       Impact factor: 2.847

Review 6.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

7.  Oxazepam kinetics: effects of age and sex.

Authors:  D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

8.  Disposition of oxazepam in relation to age, sex, and cigarette smoking.

Authors:  H R Ochs; D J Greenblatt; H Otten
Journal:  Klin Wochenschr       Date:  1981-08-17

9.  Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.

Authors:  H R Ochs; D J Greenblatt; H J Kaschell; U Klehr; M Divoll; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Renal disease, age, and oxazepam kinetics.

Authors:  T G Murray; S T Chiang; H H Koepke; B R Walker
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

View more
  2 in total

1.  Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.

Authors:  J Sennesael; D Verbeelen; L Vanhaelst; R Pirola; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Effect of cirrhosis and renal failure on the kinetics of clotiazepam.

Authors:  H R Ochs; D J Greenblatt; M Knüchel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.